Oral anti-pseudomonal antibiotics for cystic fibrosis

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis

OBJECTIVES Previous studies have examined renal safety of once daily intravenous tobramycin in individuals with cystic fibrosis. This has been mainly in combination with ceftazidime in an adolescent or adult population. In this report, we describe our institutional experience of once daily intravenous tobramycin in combination with a variety of second anti-pseudomonal antibiotics in children wi...

Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.

BACKGROUND Choice of antibiotic, and the use of single or combined therapy are controversial areas in the treatment of respiratory infection due to Pseudomonas aeruginosa in cystic fibrosis (CF). Advantages of combination therapy include wider range of modes of action, possible synergy and reduction of resistant organisms; advantages of monotherapy include lower cost, ease of administration and...

Antibiotics in Cystic Fibrosis.

IN cystic fibrosis the main problem is the susceptibility of the children to respiratory infection. The clinical course of the untreated case is one of repeated respiratory infections followed by persistent pulmonary sepsis, and later death. Severe attacks may occur in the first weeks or months of life, or less commonly, years may pass with no, or minimal symptoms referable to the chest. Upper ...

Aerosol antibiotics in cystic fibrosis.

Chronic airways infection and inflammation is the greatest source of morbidity and mortality in cystic fibrosis (CF) patients. Many organisms can be found in the lower respiratory tract of CF patients, but infection with mucoid Pseudomonas aeruginosa is common, is associated with poorer outcomes, and is the main target for antimicrobial strategies in CF. Aerosol antibiotics achieve high local c...

Macrolide antibiotics and cystic fibrosis.